On June 21, 2022 Brand Institute reported that having worked with Adello Biologics (acquired by Kashiv Biosciences in 2019) in developing the brand name FYLNETRA (pegfilgrastim-pbbk), for an injection used to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia (Press release, Brand Institute, JUN 21, 2022, View Source [SID1234616141]). In addition to working on the brand name, Brand Institute also partnered with Adello Biologics in developing the suffix "pbbk" for the non-proprietary name for FYLNETRA, pegfilgrastim-pbbk.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

FYLNETRA was developed by Kashiv Biosciences in collaboration with Amneal Pharmaceuticals. FYLNETRA is the most recent pegfilgrastim biosimilar approved by the FDA.

"The entire Brand Institute and Drug Safety Institute team congratulates Kashiv Biosciences and Amneal Pharmaceuticals on the FDA approval for FYLNETRA," said Brand Institute’s Chairman and C.E.O., James L. Dettore.